Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China To Fast-Track Approval For Hemophilia Drugs

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - In an effort to combat the domestic shortage of hemophilia treatments, China's State Food and Drug Administration announced Sept. 18 that it will fast track the approval process for Bayer Healthcare's Kogenate FS (recombinant-clotting factor VIII), which has had an application pending at SFDA since last November

You may also be interested in...

Bayer To Build Web Of Hemophilia Treatment Centers Across China

BEIJING - Bayer Schering Pharma is partnering with the Chinese Society of Hematology to build a network of hemophilia treatment centers that will crisscross China, according to a Bayer executive in Asia

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts